Paziente con disturbo duale: disturbo da uso di alcool, cocaina, cannabinoidi e disturbo depressivo. Strategie d’intervento e gestione farmacologica

Sabrina Palazzi; Roberto Poli

doi:10.3280/mis71-2025oa21195

Newsletter "Clinica dell'Alcolismo"

N. 71 (2025)

Paziente con disturbo duale: disturbo da uso di alcool, cocaina, cannabinoidi e disturbo depressivo. Strategie d’intervento e gestione farmacologica

Sabrina Palazzi^▸^▾
Roberto Poli^▸^▾

SCARICA QUI IL PDF

DOI: https://doi.org/10.3280/mis71-2025oa21195
Inviata: 4 ottobre 2025
Pubblicato: 23-10-2025

Riferimenti bibliografici

Addolorato G., Cibin M., Caputo F. et al. (1998). Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility i non-responder alcoholic patients. Drug Alcohol Depend., 53(1): 7-10.
Agabio R., Camposeragna A., Saulle R., Krupchanka D., Leggio L., Minozzi S. (2023). Combined pharmacological and psychosocial interventions for alcohol use disorder. Cochrane Database Syst Rev. (3). Doi: 10.1002/14651858.CD015673.
McCrady B.S., Flanagan J.C. (2021). The Role of the Family in Alcohol Use Disorder Recovery for Adults. Alcohol Res., 41(1): 6. Doi: 10.35946/arcr.v41.1.06.
McPheeters M., O’Connor E.A., Riley S. et al. (2023). Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings: Systematic Review. Doi: 10.23970/AHRQEPCCER262.
Patterson A., Vu M., Haardörfer R., Windle M., Berg C.J. (2020). Motives for Alcohol and Marijuana Use as Predictors of Use and Problem Use Among Young Adult College Students. J Drug Issues, 50(4): 359-377. Doi: 10.1177/0022042620917101.
Rösner S., Hackl-Herrwerth A., Leucht S., Lehert P., Vecchi S., Soyka M. (2010). Acamprosate for alcohol dependence. Cochrane database Syst Rev., (9), CD004332. Doi: 10.1002/14651858.CD004332.pub2.

Come citare

Palazzi, S., & Poli, R. (2025). Paziente con disturbo duale: disturbo da uso di alcool, cocaina, cannabinoidi e disturbo depressivo. Strategie d’intervento e gestione farmacologica. Mission - Open Access, (71). https://doi.org/10.3280/mis71-2025oa21195

[1] Addolorato G., Cibin M., Caputo F. et al. (1998). Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility i non-responder alcoholic patients. Drug Alcohol Depend., 53(1): 7-10.

[2] Agabio R., Camposeragna A., Saulle R., Krupchanka D., Leggio L., Minozzi S. (2023). Combined pharmacological and psychosocial interventions for alcohol use disorder. Cochrane Database Syst Rev. (3). Doi: 10.1002/14651858.CD015673.

[3] McCrady B.S., Flanagan J.C. (2021). The Role of the Family in Alcohol Use Disorder Recovery for Adults. Alcohol Res., 41(1): 6. Doi: 10.35946/arcr.v41.1.06.

[4] McPheeters M., O’Connor E.A., Riley S. et al. (2023). Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings: Systematic Review. Doi: 10.23970/AHRQEPCCER262.

[5] Patterson A., Vu M., Haardörfer R., Windle M., Berg C.J. (2020). Motives for Alcohol and Marijuana Use as Predictors of Use and Problem Use Among Young Adult College Students. J Drug Issues, 50(4): 359-377. Doi: 10.1177/0022042620917101.

[6] Rösner S., Hackl-Herrwerth A., Leucht S., Lehert P., Vecchi S., Soyka M. (2010). Acamprosate for alcohol dependence. Cochrane database Syst Rev., (9), CD004332. Doi: 10.1002/14651858.CD004332.pub2.